<DOC>
	<DOCNO>NCT01588470</DOCNO>
	<brief_summary>The purpose study examine existence heart abnormalities patient diabetes effect pioglitazone correct abnormality .</brief_summary>
	<brief_title>Myocardial Dysfunction Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description>PRIMARY OBJECTIVES 1 . To quantitate myocardial insulin sensitivity use positron emission tomography ( PET ) 18F-deoxyglucose type 2 diabetes mellitus ( T2DM ) control subject . 2 . To quantitate intramyocellular pericardial fat use magnetic resonance spectroscopy T2DM control subject . 3 . To quantitate cardiac function use magnetic resonance image echocardiography T2DM control subject . 4 . To examine effect pioglitazone myocardial insulin sensitivity , intramyocardial/pericardial fat content , cardiac function . SECONDARY OBJECTIVES To examine relationship myocardial insulin sensitivity , myocardial pericardial fat content , cardiac function pioglitazone treatment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Patients must able communicate meaningfully investigator must legally competent provide write informed consent . Patients may either sex . Female patient must nonlactating must either least one year postmenopausal , use adequate contraceptive precaution ( i.e . oral contraceptive , approve hormonal implant , intrauterine device , diaphragm spermicide , condom spermicide ) , surgically sterilize ( i.e . bilateral tubal ligation , bilateral oophorectomy ) . Female patient undergone hysterectomy eligible participation study . Female patient ( except patient undergone hysterectomy bilateral oophorectomy ) eligible negative pregnancy test throughout study period Patients must range age 18 75 year , inclusive . Patients type 2 diabetes must drug naïve , receive monotherapy metformin sulfonylurea , combination therapy : metformin &amp; sulfonylurea . Patients must follow laboratory value : Hematocrit ≥ 34 vol % Serum creatinine ≤ 1.8 mg/dl AST ( SGOT ) ≤ 2.5 time upper limit normal ALT ( SGPT ) ≤ 2.5 time upper limit normal Alkaline phosphatase ≤ 2 time upper limit normal Patients must stable dose allow chronic medication 30 day prior enter study . Only subject whose body weight stable ( ±34 pound ) three month prior study include . Patients must type 1 diabetes . Patients must receive medication know adverse effect glucose tolerance ( except metformin sulfonylurea ) unless patient stable dose agent past three month entry study . Patients may take stable dos estrogens hormonal replacement therapy , patient agent prior three month . Patients take systemic glucocorticoid exclude . Patients history clinically significant heart disease ( New York Heart Classification great class 2 ; nonspecific STT wave change EKG ) , peripheral vascular disease ( history claudication ) , pulmonary disease ( dyspnea exertion one flight le ; abnormal breath sound auscultation ) study . Patients hematocrit &lt; 34 % exclude . Patient expose procedure involve radiation exposure total radiation dose equivalent exceed 5 rem past year exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>diastolic function</keyword>
	<keyword>intramyocellular fat</keyword>
	<keyword>mitochondrion</keyword>
	<keyword>pioglitazone</keyword>
</DOC>